After achieving their long-awaited dream of becoming parents and cherishing the early days of their newborn daughter, Alexandre Genest and Carly Wedge faced a sudden tragedy. Lupine, their seemingly healthy baby, fell critically ill just three weeks after birth due to Group B Streptococcus (GBS), leading to sepsis and meningitis.
Despite the devastating loss of Lupine, the couple is now cycling through Nova Scotia to raise awareness and funds for the hospital that tried to save their daughter. They are also advocating for a GBS vaccine currently in development.
Dr. Joanne Langley, an infectious disease specialist, emphasizes the urgency of preventing GBS, which can progress rapidly and severely impact infants. She is leading a Phase 3 clinical trial for a maternal GBS vaccine, a significant advancement in GBS prevention efforts that could potentially save thousands of lives globally.
The World Health Organization reports that GBS causes a significant number of stillbirths and infant deaths annually, highlighting the urgent need for effective prevention measures. Langley and Pfizer are optimistic about the potential of the vaccine, which could significantly reduce infant GBS cases and associated risks.
Wedge and Genest are actively engaging with their community, sharing Lupine’s story, and advocating for participation in the vaccine trial. Their journey is not only a tribute to their daughter but also a call to action to prevent similar tragedies in the future.
As they navigate their grief and promote the vaccine, the couple remains hopeful that their efforts will contribute to a future where families are spared the pain they endured. The ongoing clinical trials offer a beacon of hope in the fight against GBS, paving the way for a safer and healthier future for mothers and newborns worldwide.